Aviado · Research
Longevity Daily
Sunday, September 27, 2026
Today's Brief
Today's edition centers on the gap between longevity hype and hard evidence. A Yale-led Nature Medicine study — our must-read — is the most systematic test yet of popular anti-aging interventions against biological age clocks. The PEARL rapamycin trial delivers the most extensive human dataset on the drug our readers ask about most, while creatine earns another quiet win for sedentary older adults. Elsewhere, the TAME metformin trial's decade-long funding failure is a cautionary tale about how the most promising longevity science gets stranded without a patent to back it.
10 stories3 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Chronic Stress Accelerates Cognitive Aging — and Social Support Can't Fully Stop It
A study of more than 3,800 adults found that chronic stress measurably accelerates cognitive decline, particularly in attention and processing speed. Social support helped slow the decline but couldn't fully shield the brain from the damage of sustained stress. For health optimizers, this reinforces that stress management isn't just a mood issue — it's a cognitive longevity strategy backed by hard population data.
Read more →Supplements & Compounds
Folic Acid Cuts Stroke Risk by Up to 25%, Meta-Analysis Finds
A meta-analysis found that folic acid supplementation reduced stroke risk by 18% to 25% — a clinically meaningful reduction. The benefit for other cardiovascular conditions was less clear, suggesting folic acid is a targeted rather than broad-spectrum cardiovascular supplement. If stroke prevention is a priority — especially for those with elevated homocysteine — this analysis provides the strongest population-level evidence yet for adding folic acid to your stack.
Read more →Creatine Preserves Lean Muscle Even Without Exercise — New Research Broadens the Case for Daily Use
A new study found that creatine supplementation maintained and increased lean mass in adults who followed no structured exercise program — a significant finding for older adults, those in recovery, or anyone with limited mobility. When combined with diet and exercise, creatine outperformed the lifestyle intervention alone on body composition. The research adds to a growing body of evidence that creatine earns a spot in the daily stack regardless of gym attendance.
Read more →Andrew Huberman Takes NMN Every Day — But Admits It Probably Won't Make Him Live Longer
Andrew Huberman continues to include NMN in his daily protocol but is publicly candid that the evidence doesn't yet support lifespan extension. A July 2026 systematic review and meta-analysis found NMN generally well-tolerated in short-term trials but found no broad metabolic benefits — a significant reality check for one of the supplement world's most hyped molecules. This is a useful reminder that "safe to take" and "proven to extend life" are very different claims.
Read more →Krill Oil Reliably Cuts Triglycerides — But Won't Touch Your Cholesterol. Here's What That Split Tells You
Across multiple high-quality studies, krill oil consistently lowers blood triglycerides but barely moves LDL or HDL cholesterol — making it one of the few supplements where you can run a clean personal experiment with a standard blood panel. Aviado's analysis recommends 2–4 grams daily with meals, then a triglyceride retest at 12 weeks: if they haven't dropped at least 10 mg/dL, the evidence says you're a non-responder. That clarity — no guesswork, no indefinite commitment — is what makes krill oil worth understanding precisely.
Read the full Aviado analysis →Research & Papers
Yale Scientists Put Popular Anti-Aging Treatments to the Test — These Are the Ones That Actually Changed Biological Age
A team from Yale School of Medicine, publishing in Nature Medicine in August 2026, systematically tested whether widely studied anti-aging strategies produce consistent changes in biological age as measured by DNA methylation clocks. The findings are nuanced: some popular interventions move different biological age clocks in conflicting directions, casting doubt on whether any single protocol works universally. Lead author Sehgal, working in Albert Higgins-Chen's lab, argues the field needs to reconcile which clock — and which intervention — actually captures meaningful aging biology. If you're tracking your own biological age, this study is essential reading for understanding which protocols have rigorous evidence behind them — and which may be producing a false sense of progress.
Read more →PEARL Trial Delivers the Most Extensive Human Dataset on Rapamycin — Results Are Promising but Nuanced
The 2025–2026 results from the PEARL trial provide the most extensive dataset yet on rapamycin use in healthy adults aged 50 to 85. While the trial showed mixed results for reducing visceral fat, it found statistically significant preservation of lean tissue mass and improvements in emotional well-being. For those following the rapamycin conversation, this is meaningful human-trial data — though it confirms the drug's effects are targeted rather than broadly transformative, and long-term safety data remain limited.
Read more →Senolytics vs. Senomorphics: The Two Strategies for Clearing Aging Cells — and Which Drugs Are Already Being Used
A clinical review in Dermatology Times outlines two distinct approaches to targeting senescent cells: senolytics that eliminate them outright, and senomorphics — including rapamycin and metformin — that suppress their inflammatory secretions without destroying the cells. Both strategies show promise for extending lifespan and reducing age-related tissue damage. If you're tracking rapamycin or metformin for longevity, this review provides a clear explanation of the specific anti-aging mechanism driving their off-label use.
Read more →Lifestyle & Nutrition
One Diet Shift Slowed Biological Aging in Just Four Weeks — in Adults Over 65
A randomized trial in adults aged 65 to 75 found that shifting to a higher-carbohydrate, lower-fat diet measurably improved biological age biomarkers in only four weeks, as measured by DNA methylation clocks. The speed of the effect is striking — though this was a short-term study, and the optimal long-term macronutrient balance for aging remains an open question. The findings suggest that biological age is more responsive to dietary shifts than many assumed, even late in life.
Read more →Industry & Policy
TAME — the Metformin Longevity Trial FDA-Cleared in 2015 — Has Still Never Enrolled a Single Patient
The Targeting Aging with Metformin (TAME) trial is widely considered the most important longevity trial ever designed — yet more than a decade after FDA clearance in 2015, it has never enrolled a patient. The reason: metformin is off-patent, so there's no commercial upside to fund it. TAME is a damning illustration of how the drug development incentive structure fails exactly when it's needed most — and a necessary corrective for anyone who believes longevity science is moving fast.
Read more →